Pivekimab sunirine (IMGN 632), an antibody-drug conjugate (ADC) that targets CD123, consists of a high-affinity CD123 antibody coupled with a cleavable linker and an indolinobenzodiazepine pseudodimer (IGN) payload. This compound is employed in the research of hematological malignancies [1] [2].

Pivekimab sunirine exhibits cytotoxicity in AML cell lines with an IC₅₀ ranging from 0.6 pM to 40 pM over an incubation period of 4-6 days [2]. Cell Viability Assay [2] was conducted on cell lines EOL-1, HNT-34, KASUMI-3, KG-1, KO52, MOLM-13, MV4-11, SHI-1, SKM-1, and UCSD-AML1 with concentrations approximately 0-1 nM.

Pivekimab sunirine, administered intraperitoneally at doses ranging from 40 to 240 μg/kg, causes tumor regression in human AML mouse xenograft models [2]. At 8 and 80 μg/kg i.p., it extends the lifespan of mice with disseminated Molm-13 xenografts [2]. In the human AML xenograft model [2], a 240 μg/kg dose leads to complete and sustained tumor regression.

Human

Monoclonal